gemini
·Code: GEM-AKI
gemini: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | Phase 2 |
FDA Decisions
FDA_MeetingAgreement on a single Adaptive design Phase 2/3 registration study and approvable composite endpoint for AKI.(REVB)
Frequently asked questions
Who is developing gemini?
gemini is being developed by REVELATION BIOSCIENCES, INC..
What is gemini's latest FDA decision?
The most recent tracked FDA decision for gemini is FDA_Meeting for Agreement on a single Adaptive design Phase 2/3 registration study and approvable composite endpoint for AKI., dated January 21, 2026.
Get deeper analysis on gemini
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis